EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): AGM/EGM/Personnel ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share.
EQS-News: Gerresheimer AG / Key word(s): AGM/EGM/AGM/EGM Gerresheimer AG: Annual General Meeting backs growth course 07.06.2023 / 16:08 CET/CEST The issuer is solely responsible for
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): AGM/EGM/AGM/EGM RHÖN-KLINIKUM Aktiengesellschaft: Annual General Meeting approves all agenda items 07.06.2023 / 15:10 CET/CEST The issuer is solely responsible
The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the
A few weeks ago, we held a webinar about ketamine regulation and the future of psychedelic medicine (for a recording, click here). At the time,
Washington’s House and Senate have both approved the “Washington Psilocybin Services Act” (SB 5263) and the bill awaits Governor Jay Inslee’s signature. Psilocybin is a
The Oregon psilocybin program has a residency requirement. I explained how it works here, and wrote “queue the crazy business structures.” Because the program is
On April 12th, Hilary Bricken moderated our firm’s webinar titled “Current Ketamine Regulations & The Future of Psychedelic Medicines.” In that webinar, Hilary, Griffen Thorne, and
There are lots of psychedelics and psychedelic adjacent substances that are not scheduled under the Controlled Substances Act (CSA). Recently I wrote about amanita muscaria